Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 252

1.

Non-alcoholic Fatty Liver Disease (NAFLD) is associated with impairment of Health Related Quality of Life (HRQOL).

Golabi P, Otgonsuren M, Cable R, Felix S, Koenig A, Sayiner M, Younossi ZM.

Health Qual Life Outcomes. 2016 Feb 9;14(1):18. doi: 10.1186/s12955-016-0420-z.

PMID:
26860700
2.

Disparate access to treatment regimens in chronic hepatitis C patients: data from the TRIO network.

Younossi ZM, Bacon BR, Dieterich DT, Flamm SL, Kowdley K, Milligan S, Tsai N, Nezam A.

J Viral Hepat. 2016 Feb 3. doi: 10.1111/jvh.12506. [Epub ahead of print]

PMID:
26840452
3.

Patient-Reported Outcomes of Elderly Adults with Chronic Hepatitis C Treated with Interferon- and Ribavirin-Free Regimens.

Younossi ZM, Stepanova M, Nader F, Henry L.

J Am Geriatr Soc. 2016 Jan 30. doi: 10.1111/jgs.13928. [Epub ahead of print]

PMID:
26825683
4.

Predictors of Inpatient Mortality and Resource Utilization for the Elderly Patients With Chronic Hepatitis C (CH-C) in the United States.

Golabi P, Otgonsuren M, Suen W, Koenig AB, Noor B, Younossi ZM.

Medicine (Baltimore). 2016 Jan;95(3):e2482. doi: 10.1097/MD.0000000000002482.

5.

Outcomes trends for acute myocardial infarction, congestive heart failure, and pneumonia, 2005-2009.

Venkatesan C, Mishra A, Morgan A, Stepanova M, Henry L, Younossi ZM.

Am J Manag Care. 2016 Jan 1;22(1):e9-e17.

6.

Mental and Emotional Impairment in Patients With Hepatitis C is Related to Lower Work Productivity.

Younossi I, Weinstein A, Stepanova M, Hunt S, Younossi ZM.

Psychosomatics. 2016 Jan-Feb;57(1):82-8. doi: 10.1016/j.psym.2015.10.005. Epub 2015 Oct 23.

PMID:
26791515
7.

Treatment strategies for chronic hepatitis C prior to and following liver transplantation.

Perumpail RB, Hahambis TA, Aggarwal A, Younossi ZM, Ahmed A.

World J Hepatol. 2016 Jan 8;8(1):69-73. doi: 10.4254/wjh.v8.i1.69. Review.

8.

Global Epidemiology of Non-Alcoholic Fatty Liver Disease-Meta-Analytic Assessment of Prevalence, Incidence and Outcomes.

Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M.

Hepatology. 2015 Dec 28. doi: 10.1002/hep.28431. [Epub ahead of print]

PMID:
26707365
9.

Advances in cirrhosis: Optimizing the management of hepatic encephalopathy.

Liu A, Perumpail RB, Kumari R, Younossi ZM, Wong RJ, Ahmed A.

World J Hepatol. 2015 Dec 18;7(29):2871-9. doi: 10.4254/wjh.v7.i29.2871. Review.

10.

Current complications and challenges in nonalcoholic steatohepatitis screening and diagnosis.

Golabi P, Sayiner M, Fazel Y, Koenig A, Henry L, Younossi ZM.

Expert Rev Gastroenterol Hepatol. 2016 Jan;10(1):63-71. doi: 10.1586/17474124.2016.1099433. Epub 2015 Oct 15.

PMID:
26469309
11.

Dysregulation of distal cholesterol biosynthesis in association with relapse and advanced disease in CHC genotype 2 and 3 treated with sofosbuvir and ribavirin.

Younossi ZM, Stepanova M, Estep M, Negro F, Clark PJ, Hunt S, Song Q, Paulson M, Stamm LM, Brainard DM, Subramanian GM, McHutchison JG, Patel K.

J Hepatol. 2016 Jan;64(1):29-36. doi: 10.1016/j.jhep.2015.08.027. Epub 2015 Sep 1.

PMID:
26341824
12.

The changing landscape of hepatitis C virus therapy: focus on interferon-free treatment.

Lam BP, Jeffers T, Younoszai Z, Fazel Y, Younossi ZM.

Therap Adv Gastroenterol. 2015 Sep;8(5):298-312. doi: 10.1177/1756283X15587481. Review.

13.

The impact of viral hepatitis-related hepatocellular carcinoma to post-transplant outcomes.

Younossi ZM, Stepanova M, Saab S, Ahmed A, Lam B, Srishord M, Venkatesan C, Wai H, Henry L.

J Viral Hepat. 2016 Jan;23(1):53-61. doi: 10.1111/jvh.12449. Epub 2015 Aug 20.

PMID:
26289820
14.

Ledipasvir/sofosbuvir treatment of hepatitis C virus is associated with reduction in serum apolipoprotein levels.

Younossi ZM, Elsheikh E, Stepanova M, Gerber L, Nader F, Stamm LM, Brainard DM, McHutchinson JG.

J Viral Hepat. 2015 Dec;22(12):977-82. doi: 10.1111/jvh.12448. Epub 2015 Aug 17.

PMID:
26280786
15.

Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009.

Younossi ZM, Otgonsuren M, Henry L, Venkatesan C, Mishra A, Erario M, Hunt S.

Hepatology. 2015 Dec;62(6):1723-30. doi: 10.1002/hep.28123. Epub 2015 Oct 24.

PMID:
26274335
16.

Effects of Viral Eradication With Ledipasvir and Sofosbuvir, With or Without Ribavirin, on Measures of Fatigue in Patients With Chronic Hepatitis C Virus Infection.

Gerber L, Estep M, Stepanova M, Escheik C, Weinstein A, Younossi ZM.

Clin Gastroenterol Hepatol. 2016 Jan;14(1):156-164.e3. doi: 10.1016/j.cgh.2015.07.035. Epub 2015 Aug 1.

PMID:
26241510
17.

Economic and Quality-of-Life Implications of Non-Alcoholic Fatty Liver Disease.

Younossi ZM, Henry L.

Pharmacoeconomics. 2015 Dec;33(12):1245-53. doi: 10.1007/s40273-015-0316-5.

PMID:
26233836
18.

HCV infection is associated with lower survival in simultaneous liver kidney transplant recipients in the United States.

Perumpail RB, Wong RJ, Scandling JD, Ha le D, Todo T, Bonham CA, Saab S, Younossi ZM, Ahmed A.

Clin Transplant. 2015 Oct;29(10):920-6. doi: 10.1111/ctr.12598. Epub 2015 Aug 29.

PMID:
26205329
19.
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk